Severe clinical events in the treatment of Fabry disease

  • César Ballena-Custodio Servicio de Nefrología, Hospital Almanzor Aguinaga Asenjo, Chiclayo, Perú
  • Evelyn Severino-Fuentes Médico Veterinario, Municipalidad Distrital de Tumán, Perú
Keywords: Fabry disease; vascular events

References

1) Jaurretche SP. Enfermedad vascular en pacientes varones con enfermedad de Fabry en hemodiálisis: estudio de cohorte retrospectivo en Argentina. Rev Nefrol Dial Traspl. 2019;39(2):101-7.

2) Hopkin RJ, Cabrera G, Charrow J, Lemay R, Martins AM, Mauer M, et al. Risk factors for severe clinical events in male and female patients with Fabry disease treated with agalsidase beta enzyme replacement therapy: Data from the Fabry Registry. Mol Genet Metab. 2016;119(1-2):151-9.

3) Álvarez de Mon Soto M, Navas Serrano VM, Plaza Romero S (coord.). Enfermedades lisosomales. Madrid: Springer Healthcare Ibérica, 2017. 512 p.

4) Ortiz A, Abiose A, Bichet DG, Cabrera G, Charrow J, Germain DP, et al. Time to treatment benefit for adult patients with Fabry disease receiving agalsidase β: data from the Fabry Registry. J Med Genet. 2016 Jul;53(7):495-502.

5) Ortiz A, Sanchez-Niñoa MD. Diagnóstico y tratamiento de la enfermedad de Fabry. Med Clin (Barc.). 2017;148(3):132-8.
Published
2020-09-10
How to Cite
1.
Ballena-Custodio C, Severino-Fuentes E. Severe clinical events in the treatment of Fabry disease. Rev Nefrol Dial Traspl. [Internet]. 2020Sep.10 [cited 2024Jul.16];40(1):90-1. Available from: http://revistarenal.org.ar/index.php/rndt/article/view/511
Section
Letter to the Editor